ResMed Inc.’s RMD growth in the fourth quarter of fiscal 2025 can be attributed to the robust performance of its Mask business. Its recovery in the Device business continues to drive overall revenue ...
New global clinical insights initiative debuts at World Sleep Congress 2025 to help drive innovation in sleep health careSAN DIEGO, Sept. 03, 2025, a global clinical insights initiative dedicated to a ...
So unless ResMed Inc. sees its shares fall 34% and the contract is exercised (resulting in a cost basis of $136.20 per share before broker commissions, subtracting the $8.80 from $145), the only ...
ResMed Inc RMD posted Q3 profits of $247.8 million, with adjusted EPS of $1.68, up from $1.32 a year ago, beating the consensus of $1.59. Revenues increased 29% to $1.12 billion, as continued ...
ResMed Inc. is downgraded from buy to watchful hold due to valuation concerns, despite strong financial performance and growth potential. Explore more details here.
Needham upgraded ResMed Inc RMD from a Hold to Buy rating with a price target of $180. The analysts Mike Matson, Joseph Conway, and David Saxon note that ResMed's shares are down 31% since the ...
Medical equipment maker ResMed Inc said on Tuesday it will buy German healthcare software provider MEDIFOX DAN GmbH in a $1 billion deal to expand in software-as-a-service (SaaS) outside the ...
RESMED INC 競合他社・同業他社分析 - Industrial Applications and Services セクター
Our AI model demonstrates 51% historical accuracy for RMD predictions, based on advanced machine learning algorithms trained on over 10 years of market data.
VAR_0__株価予測に影響を与える要因は何か?
当社の分析では、RESMED INCの財務指標、Industrial Applications and Servicesセクターの動向、市場センチメント、テクニカル指標、業績データ、株価に影響を与えるマクロ経済要因を考慮しています。